The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial.
 
Enrique Grande
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Pfizer
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Pfizer
Research Funding - GlaxoSmithKline
 
Daniel E. Castellano
No Relationships to Disclose
 
Ana B. Custodio
No Relationships to Disclose
 
Rocio Garcia-Carbonero
Research Funding - Ipsen
Travel, Accommodations, Expenses - Ipsen; Novartis; Pfizer
 
Encarnación González
No Relationships to Disclose
 
Carlos López-López
Consulting or Advisory Role - Amgen
Speakers' Bureau - Amgen; Ipsen; Pfizer; Roche
Research Funding - Amgen; Ipsen; Pfizer; Roche
 
Javier Munarriz
No Relationships to Disclose
 
Isabel Sevilla
Speakers' Bureau - Ipsen; Novartis; Pfizer
 
Alexandre Teule
Travel, Accommodations, Expenses - Ipsen; Novartis; Pfizer
 
Marta Benavent Viñuales
No Relationships to Disclose
 
Teresa Alonso
No Relationships to Disclose
 
Pablo Gajate Borau
No Relationships to Disclose
 
José Palacios
No Relationships to Disclose
 
Jaume Capdevila
No Relationships to Disclose